The Potential of CAR-Modified T Cells in Hematologic Cancers
Renier J. Brentjens, MD, PhD, discusses the potential of using CAR-modified T cells to treat hematologic cancers.
Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses the potential of using CAR-modified T cells to treat hematologic cancers.
Clinical Pearls
- If utilized in the proper context, CAR-modified T cells have a role in the treatment of CLL
- CAR-modified T cells have the potential to become the standard of care for the treatment of relapsed B-cell acute lymphoblastic leukemia (ALL)
- Researchers are still learning how to optimize the best way of infusing the cells to get the best response rates
- Pharmaceutical companies are starting to gain interest in cellular therapies because of its potential to treat B-cell cancers as well as other types of cancer
Related Videos
Related Content
